Using a fecal test to reduce unnecessary colonoscopies after polyp removal
Official title: Fecal Immunochemical Test for Post-polypectomy Surveillance to Reduce Unnecessary eNdoscopy (FIT2RUN Study)
Run by University of Calgary · NCT05396560 · Data updated 2026-11-12
This study is testing whether a simple stool test can help people with a history of polyps or family history of colorectal cancer avoid unnecessary colonoscopies.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 74 Years |
| Sex | All |
| Enrollment | 3000 (estimated) |
| Sponsor | University of Calgary Academic / other |
| Locations | 1 site (Calgary, Alberta) |
| Status | Recruiting |
| Started | April 15, 2022 |
| Main results expected | April 15, 2026 |
| Study ends | April 15, 2027 |
| Registry record updated | May 31, 2022 |
| Trial ID | NCT05396560 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include men and women aged 74 or younger with a personal or family history of colorectal polyps or cancer.
✕Probably not a fit
Patients with known genetic syndromes, recent colonoscopy, or those unable to provide informed consent may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to estimate the prevalence of advanced colorectal neoplasia in patients with a history of polyps or family history of colorectal cancer. It will evaluate the performance of Fecal Immunochemical Tests (FIT) as a potential alternative to colonoscopy for ongoing surveillance. By developing a risk prediction model, the study seeks to guide the choice between FIT and colonoscopy, addressing the growing demand for colonoscopy resources. The goal is to improve access to colonoscopy while reducing costs associated with surveillance.
Why it matters
Potential benefit: If successful, this approach could provide a less invasive and more cost-effective method for monitoring patients at risk for colorectal cancer.
How similar studies have gone: Other studies have explored the use of FIT in colorectal cancer screening, showing promising results, but this specific application for post-polypectomy surveillance is less established.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Men or women age ≤ 74 years of age. 2. At least one risk factor for CRC that would generally lead to colonoscopy screening: 1. Personal history of low risk polyps 2. Personal history of high risk polyps 3. Family history of CRC or polyps Exclusion Criteria: 1. Known acromegaly, cystic fibrosis or high risk profession (firefighter) 2. Referred for colonoscopy due to a positive fecal immunochemical test or CT colonography 3. Known or suspected gene carrier for a familial cancer syndrome. 4. Does not meet medical criteria for colonoscopy at the CCSC. 5. Colonoscopy within the previous 30 months 6. Unable to provide written informed consent or complete questionnaires due to language barrier or other reasons.
Where it's running
-
Forzani & Macphail Colon Cancer Screening Centre, University of Calgary
Calgary, Alberta, Canada Recruiting
Study contacts
- Principal investigator: Robert Hilsden, MD PhD — University of Calgary
- Study coordinator: Robert Hilsden, MD PhD
- Email: rhilsden@ucalgary.ca
- Phone: 403-592-5089
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Biomarkers in Colorectal Cancer: A Longitudinal Study Using Biobanks and Blood Samples
This study tests whether clinical and molecular biomarkers from tumor tissue and blood can predict treatment response, recurrence, and survival in adults with colorectal cancer undergoing surgery.
-
Prehabilitation with Resistance, Aerobic, or Both Before Colorectal Surgery
Four pre-surgery exercise options (resistance, aerobic, both, or none) will be tested to see which best reduces complications after colorectal cancer surgery.
-
ctDNA blood test to spot buried cancer after surgery or treatment in colorectal cancer
A blood test that looks for specific KRAS mutations in circulating tumor DNA to see if colorectal cancer has left residual disease or is likely to relapse.
-
Multimodal Survival Predictor for Colorectal Liver Metastases After Surgery
Researchers are testing a tool that combines MRI-derived tumor features with clinical data to predict survival after surgery for colorectal liver metastases.
-
Methylscape test in body fluids for multi-cancer detection in Colombia
A simple blood, urine, or saliva test called Methylscape is being tested to see if it can detect multiple cancers and identify where the signal is coming from, using people with cancer and healthy volunteers in Colombia.
-
AI-powered stool image analysis to see if it matches FIT results in colorectal cancer screening
We’re testing whether AI-derived features from stool images can align with FIT results in adults being screened or evaluated for colorectal neoplasia.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.